To safeguard human health, food systems, and economies through rapid, scalable, and accurate pathogen detection.
Global Biosecurity Starts with Scalable Diagnostics
Avicena is an ISO 13485-certified Australian medical technology company developing advanced molecular diagnostic and biosecurity systems to protect communities and economies from disease outbreaks.
Our Sentinel platform is the next generation in pathogen detection – automated, accurate, scalable, and suitable for both human and animal applications. Built on LAMP technology, it delivers PCR-level sensitivity and adapts easily to a wide range of pathogens.
Headquartered in Perth, Australia, Avicena is expanding into the UK, US, and Middle East, partnering with governments, health providers, and industry to deliver scalable diagnostics through flexible business models including sales, rentals, and long-term service contracts.
The World’s Most Scalable Pathogen Detection Platform
At the heart of Avicena is the Sentinel platform, the most scalable rapid molecular diagnostic system in the world.
Built around our continuous-flow LAMP technology, Sentinel delivers PCR-level accuracy with unmatched speed – processing up to 100,000 samples per day with results in under 30 minutes.
From hospitals to airports, to rural communities and forward military bases, our instruments operate in ways conventional labs cannot.
Leading the Future of Diagnostics
Avicena brings together a cross-disciplinary, world-class team of scientists, engineers, and commercial leaders.
Our executive team brings global experience in medical diagnostics, biotechnology, and advanced engineering – spanning product development, regulatory strategy, large-scale manufacturing, and commercial rollout.
ISO 13485 certified for the design, development, and manufacture of in vitro diagnostics
CE-Marked for use in the in vitro diagnostic (IVD) molecular testing
Avicena holds several patent pending innovations that enable our groundbreaking performance.
Validation of a rapid, saliva-based, and ultra-sensitive SARS-CoV-2 screening system for pandemic-scale infection surveillance. Dewhurst RE, et al. 2022. Nature, Scientific Reports.
